Neurol. pro Praxi, 2007; 1: 49-54

Diabetes mellitus: současný pohled na patogenezi, klasifikaci a léčbu

prof. MUDr. Michal Anděl, CSc., MUDr. Ludmila Brunerová, Ph.D., MUDr. Jan Novák, MUDr. Marcela Hašpicová, MUDr. Ludmila Trešlová
Diabetologické centrum a 2. interní klinika Fakultní nemocnice Královské Vinohrady a 3. lékařské fakulty Univerzity Karlovy

Epidemie diabetu, která probíhá v rozvinutých zemích, představuje jedno z nejvážnějších zdravotních, sociálních i ekonomických rizik pro obyvatelstvo těchto zemí. Diabetes mellitus 1.a 2. typu jsou onemocnění se zásadně rozdílnou etiologií a patogenezí. Důsledky zvýšené glykémie vedou často k podobným komplikacím. Zatímco v patogenezi diabetu 1. typu je zásadní autoimunní inzulitida, která vede k destrukci beta-buněk Langerhansových ostrůvků pankreatu, v patogenezi diabetu 2. typu hraje dominantní roli inzulínová rezistence, spojená v převážné části případů s obezitou či nadváhou. V prevenci makro- i mikrovaskulárních komplikací hraje zásadní úlohu udržování glykémie co nejbližší normálním hodnotám u zdravých osob a normální arteriální krevní tlak.

Keywords: diabetes mellitus 1. typu, diabetes mellitus 2. typu, komplikace, prevence, léčba

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Anděl M, Brunerová L, Novák J, Hašpicová M, Trešlová L. Diabetes mellitus: současný pohled na patogenezi, klasifikaci a léčbu. Neurol. praxi. 2007;8(1):49-54.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anděl M et al. Diabetes mellitus a další poruchy metabolismu. Praha: Galén 2001. 208 s.
    2. Atkinson MA, Maclaren NK. The pathogenesis of insulin - dependent diabetes mellitus. N Engl J Med 1994; 331: 1428-1436. Go to original source... Go to PubMed...
    3. Bartoš V, Pelikánová T. Praktická diabetologie. Praha: Maxdorf 2001.
    4. Bell JL, Hockaday TD. Diabetes mellitus. In: Wheatherall DJ, Leham JGG, Warell DA. Oxford Textbook of Medicine. Oxford: Oxford University Press 1996: 1448-1504.
    5. Campbell RK, White JR Jr, Saulie BA. Metformin: A new oral biguanide. Clin Ther 1996; 18: 360-371. Go to original source... Go to PubMed...
    6. Dhindsa G, Bhatia R, Dhindsa M, Bhatia V. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome. J Postgrad Med 2004; 50: 140-144.
    7. De Fronzo RA, Goodmann AM. Efficacy of metformin in patiens with non - insulin - dependent diabetes mellitus :the Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549. Go to original source... Go to PubMed...
    8. Foster DW. Diabetes Mellitus. In: Braunwald E, Iselbacher KJ, Pedorf RG, Wilson JD, Martin JB, Fausi AS (Eds). Harrison s Principles of Internal Medicine. New York: Mc Graw Hill Book Co 1987: 1778-1797.
    9. Harris MI, Zimmet P. Classification of diabetes mellitus and other categories of glucose intolerance. In: Keen H, DeFronzo R, Alberti KGMM, Zimmet P (Eds.). The International Textbook of Diabetes Mellitus. London: Wiley 1992: 3-18.
    10. Jarret RJ. The Epidemiology of Diabetes Mellitus. In: Pickup JC, Williams G. Textbook of Diabetes Mellitus. Oxford: Blackwell 1991: 47-53.
    11. Kučera P, Anděl M, Trešlová L. Autoimunita a protilátky proti glutamátdekarboxyláze v patogenezi diabetes mellitus I. typu v experimentu a klinické praxi. Vnitř lék 1996; 42: 359-367. Go to PubMed...
    12. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, D´Onofrio F. Metformin for obese, insulin treated diabetic patiens: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44: 107-112. Go to original source... Go to PubMed...
    13. Hsueh WA, Law RE. Cardiovascular risk continuum : Implications of insulin resistence and diabetes. Am J Med 1998; 105: 4-14. Go to original source... Go to PubMed...
    14. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA 2002; 287: 360-372. Go to original source... Go to PubMed...
    15. Kučera P. Stanovení protilátek proti glutamát dekarboxylase v periferní krvi metodou ELISA. Klin Biochem Metab 1996; 4: 195-197.
    16. Mannuci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Messeri G, Rostella C. Efect of Metformin on Glucagon - Lik Peptid 1 (GLP - 1) and Leptin Levels in Obese Nondiabetic Subjects. Diabetes Care 2001; 24: 489-494. Go to original source... Go to PubMed...
    17. Quillen DM, Kuritzky L. Type 2 diabetes management: A comprehensive clinical review of oral medications. Compr Ther 2002; 28: 50-61. Go to original source... Go to PubMed...
    18. Sasali A, Leahy JL. Is metformin cardioprotective? Editorial. Diabetes Care 2003; 26: 243-244. Go to original source... Go to PubMed...
    19. Scheen AJ, Lefebvre PJ. Antihyperglycemic agents. Drug interactions of clinical importace. Drug Saf 1995; 12: 32-45. Go to original source... Go to PubMed...
    20. Wallace TM, Metthews DR. The drug treatment of type 2 diabetes. In: Pickup JC, Williams G. Textbook of diabetes. Part II. Oxford: Blackwell 2003; 45: 1-18.
    21. Zimmet P. The pathogenesis and prevention of diabetes in adults : genes, autoimmunity and demography. Diabetes Care 1995; 18: 1050-1064. Go to original source... Go to PubMed...
    22. Zimmet P, Turner R, McCarty D, Rowley M, Mackay I. Crucial Points at Diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999; 22 (Suppl 2): 59-64.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.